Active Ingredient(s): Lasmiditan Succinate
FDA Approved: * October 11, 2019
Pharm Company: * ELI LILLY AND CO
Category: Migraine / Tension Headache

Lasmiditan, sold under the brand name Reyvow, is a medication used for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults.[2] It is not useful for prevention.[2] It is taken by mouth.[2] Common side effects include sleepiness, dizziness, tiredness, and numbness.[3][4] Lasmiditan was approved in the United States in October 2019 ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Reyvow 50 mg Oral Tablet
NDC: 0002-4312
Eli Lilly and Company
Reyvow 100 mg Oral Tablet
NDC: 0002-4491
Eli Lilly and Company
Reyvow 200 mg Oral Tablet
NDC: 0002-4736
Eli Lilly and Company